JP2005515244A5 - - Google Patents

Download PDF

Info

Publication number
JP2005515244A5
JP2005515244A5 JP2003561613A JP2003561613A JP2005515244A5 JP 2005515244 A5 JP2005515244 A5 JP 2005515244A5 JP 2003561613 A JP2003561613 A JP 2003561613A JP 2003561613 A JP2003561613 A JP 2003561613A JP 2005515244 A5 JP2005515244 A5 JP 2005515244A5
Authority
JP
Japan
Prior art keywords
active ingredient
leishmaniasis
miltefosine
perifosine
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003561613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515244A (ja
Filing date
Publication date
Priority claimed from DE10203195A external-priority patent/DE10203195A1/de
Application filed filed Critical
Publication of JP2005515244A publication Critical patent/JP2005515244A/ja
Publication of JP2005515244A5 publication Critical patent/JP2005515244A5/ja
Pending legal-status Critical Current

Links

JP2003561613A 2002-01-25 2003-01-07 原虫症の予防的処置のためのアルキルホスホコリンの使用 Pending JP2005515244A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10203195A DE10203195A1 (de) 2002-01-25 2002-01-25 Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
PCT/EP2003/000072 WO2003061669A1 (de) 2002-01-25 2003-01-07 Verwendung von alkylphosphocholinen in der präventivbehandlung von protozoenerkrankungen

Publications (2)

Publication Number Publication Date
JP2005515244A JP2005515244A (ja) 2005-05-26
JP2005515244A5 true JP2005515244A5 (https=) 2006-01-05

Family

ID=7713213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003561613A Pending JP2005515244A (ja) 2002-01-25 2003-01-07 原虫症の予防的処置のためのアルキルホスホコリンの使用

Country Status (16)

Country Link
EP (1) EP1467742A1 (https=)
JP (1) JP2005515244A (https=)
CN (1) CN1622811A (https=)
AR (1) AR038224A1 (https=)
AU (1) AU2003236787B2 (https=)
BR (1) BR0307021A (https=)
CA (1) CA2470185A1 (https=)
CO (1) CO5601024A2 (https=)
DE (1) DE10203195A1 (https=)
IL (2) IL162492A0 (https=)
MX (1) MXPA04007193A (https=)
NZ (1) NZ548040A (https=)
PE (1) PE20030732A1 (https=)
TW (1) TWI339582B (https=)
WO (1) WO2003061669A1 (https=)
ZA (1) ZA200404690B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT501545B1 (de) * 2005-02-23 2007-10-15 Obwaller Andreas Dr Reinigungsmittel für kontaktlinsen
CA2632449A1 (en) * 2005-12-19 2007-06-28 Aeterna Zentaris Gmbh Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4132345A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Ether-lysolecithine und alkylphosphocholine in liposomen
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
BR9306040A (pt) * 1992-03-06 1997-11-18 Statens Seruminstitut Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias
ES2175663T3 (es) * 1998-01-22 2002-11-16 Zentaris Ag Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
DE10020812C2 (de) * 2000-04-20 2003-06-26 Robert Koch Inst Verwendung von Naphthindazol-4,9-chinonen als Antiparasitika
AU2002232400A1 (en) * 2000-11-06 2002-05-15 U.S. Army Medical Research And Materiel Command Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis

Similar Documents

Publication Publication Date Title
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JPH06102622B2 (ja) 肥満の治療
JPH032126A (ja) 口腔内抗真菌予防薬およびその使用法
DE69615704D1 (de) Bioadhesive feste arzneimittelform
CA2277365A1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
BG105173A (en) Novel salt form of pantoprazole
AP1849A (en) Dosage regimen and pharmaceutical composition for emergency contraception
SE9901573D0 (sv) New compounds
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
MA63248B1 (fr) Formulations d'un inhibiteur de la kallicréine plasmatique
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP2010511039A5 (https=)
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
WO2004050025A3 (en) Combination of ibuprofen and oxycodone for acute pain relief
RU2003125274A (ru) Применение флумазенила в производстве лекарства для лечения алкогольной зависимости
JP2002540148A5 (https=)
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
JP2005515244A5 (https=)
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
EP4494700A3 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
SE9901572D0 (sv) New compounds
SI9620036B (sl) Derivat aminotetralina za terapijo kardiovaskularnih bolezni
US5432187A (en) Benzimidazole anthelmintic in the treatment of microsporidial infections